Back to top
more

ObsEva SA (OBSV)

(Delayed Data from NSDQ)

$13.89 USD

13.89
12,706

-0.12 (-0.86%)

Updated May 3, 2019 04:13 PM ET

After-Market: $13.76 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

ObsEva SA (OBSV) delivered earnings and revenue surprises of 7.14% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy

by Zacks Equity Research

ObsEva SA (OBSV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids

by Zacks Equity Research

ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.

ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids

by Zacks Equity Research

ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.

Is the Options Market Predicting a Spike in ObsEva (OBSV) Stock?

by Zacks Equity Research

Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.

Implied Volatility Surging for ObsEva (OBSV) Stock Options

by Zacks Equity Research

Investors need to pay close attention to ObsEva (OBSV) stock based on the movements in the options market lately.

ObsEva (OBSV) Catches Eye: Stock Jumps 5.1%

by Zacks Equity Research

ObsEva (OBSV) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

How ObsEva (OBSV) Stock Stands Out in a Strong Industry

by Zacks Equity Research

ObsEva (OBSV) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

Catabasis (CATB) Partners with UK-Based Charity for DMD Study

by Zacks Equity Research

Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.

ObsEva Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

ObsEva has been struggling lately, but the selling pressure may be coming to an end soon.

ObsEva Enters Oversold Territory

by Zacks Equity Research

ObsEva SA has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

ObsEva SA (OBSV) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

ObsEva SA (OBSV) delivered earnings and revenue surprises of 23.17% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

ObsEva SA (OBSV) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

ObsEva SA (OBSV) delivered earnings and revenue surprises of -37.93% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ObsEva Ends Recruitment in Second Uterine Fibroids Study

by Zacks Equity Research

ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.

ObsEva SA (OBSV) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

ObsEva SA (OBSV) delivered earnings and revenue surprises of -18.00% and -50.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

ObsEva SA (OBSV) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

ObsEva SA (OBSV) delivered earnings and revenue surprises of 8.70% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

ObsEva Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

ObsEva has been struggling lately, but the selling pressure may be coming to an end soon.

ObsEva (OBSV) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in ObsEva SA (OBSV).

    Can the Rally in ObsEva (OBSV) Shares Continue?

    by Zacks Equity Research

    ObsEva SA (OBSV) has been on the move lately as the stock has risen by 22.7% in the past four weeks, and it is currently trading well above its 20-Day SMA.

      ObsEva SA (OBSV) Reports Q2 Loss, Misses Revenue Estimates

      by Zacks Equity Research

      ObsEva SA (OBSV) delivered earnings and revenue surprises of 9.26% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        ObsEva SA (OBSV) Sees Hammer Chart Pattern: Time to Buy?

        by Zacks Equity Research

        ObsEva has been struggling lately, but the selling pressure may be coming to an end soon.

          What Falling Estimates & Price Mean for ObsEva (OBSV)

          by Zacks Equity Research

          ObsEva SA (OBSV) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.